Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer
J. A. Engelman, Toru Mukohara, Kreshnik Zejnullahu et al. · Journal of Clinical Investigation · 2006
EGFR is frequently mutated and amplified in lung adenocarcinomas sensitive to EGFR inhibitors gefitinib and erlotinib.A secondary mutation, T790M, has been associated with acquired resistance but has not been shown to be sufficient to render EGFR mutant/amplified lung cancers resistant to EGFR inhibitors.We created a model for studying acquired resistance to gefitinib by prolonged exposure of a gefitinib-sensitive lung carcinoma cell line (H3255; EGFR mutated and amplified) to gefitinib in vitro.The resulting resistant cell line acquired a T790M mutation in a small fraction of the amplified alleles that was undetected by direct sequencing and identified only by a highly sensitive HPLC-based technique.In gefitinib-sensitive lung cancer cells with EGFR mutations and amplifications, exogenous introduction of EGFR T790M effectively conferred resistance to gefitinib and continued ErbB-3/PI3K/Akt signaling when in cis to an activating mutation.Moreover, continued activation of PI3K signaling by the PIK3CA oncogenic mutant, p110α E545K, was sufficient to abrogate gefitinib-induced apoptosis.These findings suggest that allelic dilution of biologically significant resistance mutations may go undetected by direct sequencing in cancers with amplified oncogenes and that restoration of PI3K activation via either a T790M mutation or other mechanisms can provide resistance to gefitinib.Nonstandard abbreviations used: ca-Akt, constitutively active Akt; Del/T790M, EGFR with a T790M mutation cis to an exon 19 deletion mutation; DHPLC, denaturing HPLC; GR, gefitinib resistant; L858R/T790M, EGFR with a T790M mutation cis to an L858R mutation; MTS, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium; NSCLC, non-small cell lung carcinoma (cancer); p-, phosphorylated; PARP, poly ADP-ribose polymerase; PTEN, phosphatase and tensin homolog; shRNA, short hairpin RNA; TKI, tyrosine kinase inhibitor; WT/T790M, WT EGFR with a T790M mutation. Conflict of interest: Pasi A. Jänne and Bruce E. Johnson are part of a pending patent application on EGFR mutations.
Cited by 456 works. doi:10.1172/jci28656 Open-access PDF
Authors
- J. A. Engelman
- Toru Mukohara
- Kreshnik Zejnullahu
- Eugene Lifshits
- Ana M. Borras
- Christopher-Michael Gale
- George N. Naumov
- Beow Yong Yeap
- E. Jarrell
- John Victor Heymach
- Bruce Evan Johnson
- Lewis C. Cantley
- Pasi Antero Janne
References
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
- Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
- Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer
- Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
- Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer
- EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
- High Frequency of Mutations of the PIK3CA Gene in Human Cancers
- Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain